Advertisement

Annals of Hematology

, Volume 69, Issue 1, pp S1–S6 | Cite as

Role of protein kinases in antitumor drug resistance

  • H. Grunicke
  • J. Hofmann
  • I. Utz
  • F. überall
First Workshop of CSG-CR

Summary

The activity of several proteins involved in the development of antitumor drug resistance is regulated by protein phosphorylation. These proteins include the mdr-1-encoded P-glycoprotein (Pgp) and topoisomerase II (topo II). The corresponding evidence is reviewed and attempts to modulate multidrug resistance (MDR) by protein kinase C inhibitors are described. The expression of several proteins which are essential in drug resistance is regulated at the transcriptional level, involving protein phosphorylation by members of the protein kinase C (PKC) family, casein kinase II (CKII), and others. These proteins include mdr-1-encoded P-glycoprotein, metallothionein, glutathione S-transferase (GST), dTMP synthase, and the proteins Fos and Jun. The corresponding genes are under positive regulation of ras, which in turn requires the activation of a protein kinase cascade for its function. Protein kinases are therefore potentially useful targets in reducing the expression of proteins involved in the development of multifactorial drug resistance caused by the expression of transforming ras-genes. Attempts to inhibit the ras-induced fos expression by an inhibitor of protein kinase C (ilmofosine) are described. Protein kinase inhibitors are also able to synergistically enhance the cytotoxicity of ds-platinum, which is discussed as resulting from a reduction of PKC-dependent fos expression.

Keywords

Public Health Protein Kinase Glutathione Drug Resistance Kinase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
CSG-CR

Cooperative Study Group — Cellular Resistance

References

  1. 1.
    Ackerman P, Glover CVC, Osheroff N (1988) Phosphorylation of DNA topoisomerase II in vivo and in total homogenates ofDrosophila Kc cells. J Biol Chem 263:12653–12660Google Scholar
  2. 2.
    Ackermann P, Glover CVC, Osheroff N (1985) Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci USA 82:3164–3168Google Scholar
  3. 3.
    Ahmad S, Glazer RI (1993) Expression of the antisense cDNA for protein kinase Cα attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43:858–862Google Scholar
  4. 4.
    Baguley BC, Finlay GJ, Ching LM (1992) Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. Oncol Res 4:267–274Google Scholar
  5. 5.
    Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B (1988) Prolactine regulation ofΒ-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 7:2089–2095Google Scholar
  6. 6.
    Blenis J (1993) Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 90:5889–5892Google Scholar
  7. 7.
    Chin KV, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459–462Google Scholar
  8. 8.
    Cornwell MM, Smith DE (1993) A signal transduction pathway for activation of the mdrl promoter involves the protooncogene c-raf kinase. J Biol Chem 268:15347–15350Google Scholar
  9. 9.
    Darkin-Rattray SJ, Ralph RK (1991) Evidence that a protein kinase enhances amsacrme-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei. Biochim Biophys Acta 1088:285–291Google Scholar
  10. 10.
    Delage S, Chastre E, Empereur S, Wicek D, Veissiére D, Capeau J, Gespach C, Cherqui G (1993) Increased protein kinase Cα expression in human colonic caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes. Cancer Res 53:2762–2770Google Scholar
  11. 11.
    DeVore RF, Corbett AH, Osheroff N (1992) Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 52:2156–2161Google Scholar
  12. 12.
    Doppler W, Jaggi R, Groner B (1987) Induction of v-mos and Ha-ras oncogene expression in quiescent NIH 3T3 cells causes intracellular alkalinization and cell cycle progression. Gene 54:145–151Google Scholar
  13. 13.
    Fan D, Fidler IJ, Ward NE, Scid C, Earnest LE, Housey GM, O'Brian CA (1992) Stable expression of a cDNA encoding rat brain protein kinase C-ΒI confers a multidrug-resistant phenotype on rat fibroblasts. Anticancer Res 12:661–668Google Scholar
  14. 14.
    Fine RL, Patel J, Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci (USA) 85:582–586Google Scholar
  15. 15.
    Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199Google Scholar
  16. 16.
    Funato T, Yoshida E, Jiao L, Tone K, Kashani-Sabet M, Scanion KJ (1992) The utility of an anti-fos ribozyme in reversing cis platin resistance in human carcinomas. Adv Enz Regul 32:195–209Google Scholar
  17. 17.
    Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427Google Scholar
  18. 18.
    Grunicke H, überall F (1992) Protein kinase C modulation. Semin Cancer Biol 3:351–360Google Scholar
  19. 19.
    Grunicke HH, Hofmann J, Maly K, Oberhuber H, überall F, Egle A, Demuth L (1991) Enhancement of the antiproliferative effect ofcis-diamminedichloroplatinum(II) and other antitumor agents by inhibitors of enzymes involved in growth factor signal transduction. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum, New York, pp 161–172Google Scholar
  20. 20.
    Grunicke HH, Maly K (1993) Role of GTPases and GTPase regulatory proteins in oncogenesis. Crit Rev Oncogenesis 4:389–402Google Scholar
  21. 21.
    Hamada H, Hagiwara KI, Nakajima T, Tsuruo T (1987) Phosphorylation of the Mr 170000 to 180 000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 47:2860–2865Google Scholar
  22. 22.
    Heck MMS, Hittelman WN, Earnshaw WC (1989) In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. J Biol Chem 264:15161–15164Google Scholar
  23. 23.
    Hofmann J, Doppier W, Jakob A, Maly K, Posch L, überall F, Grunicke HH (1988) Enhancement of the antiproliferative effect ofcis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382–388Google Scholar
  24. 24.
    Hofmann J, überall F, Posch L, Maly K, Herrmann DBJ, Grunicke H (1989) Synergistic enhancement of the antiproliferative activity ofcis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids 24:312–317Google Scholar
  25. 25.
    Hofmann J, überall F, Egle A, Grunicke H (1991) B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. Int J Cancer 47:870–874Google Scholar
  26. 26.
    Hofmann J, Wolf A, Spitaler M, Böck G, Drach J, Ludescher C, Grunicke H (1992) Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 118:361–366Google Scholar
  27. 27.
    Isabella P, Caprancio G, Zunino F (1991) The role of topoisomerase II in drug resistance. Life Sci 48:2195–2205Google Scholar
  28. 28.
    Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity tocis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-0-tetradecanoylphorbol-13-acetate. J Biol Chem 265:3623–3627Google Scholar
  29. 29.
    Isonishi S, Horn DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB (1991) Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51:5903–5909Google Scholar
  30. 30.
    Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793–6799Google Scholar
  31. 31.
    Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D, Rapp UR (1993) Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature 364:249–252Google Scholar
  32. 32.
    Kroll DJ, Rowe TC (1991) Phosphorylation of DNA topoisomerase II in a human tumor cell line. J Biol Chem 266:7957–7961Google Scholar
  33. 33.
    Mattern J, Volm M (1993) Multiple-pathway drug resistance (review). Int J Oncol 2:557–561Google Scholar
  34. 34.
    Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Carvatti G, Matter A (1989) A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative as well as in vivo antitumor activity. Int J Cancer 43:851–856Google Scholar
  35. 35.
    Murren JR, Hait WN (1992) Why haven't we cured multidrug resistant tumors? Oncol Res 4:1–6Google Scholar
  36. 36.
    Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Anrulis IK, Gazdar AF, Willman CL, Griffith B, von Hoff DD, Robinson IB (1990) Quantitative analysis of MDR-1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160–7164Google Scholar
  37. 37.
    Peters GJ, Wets M, Keepers YPAM, Oskam R, Ark-Otte J, Noordhuis P, Smid K, Pinedo HM (1993) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54:450–455Google Scholar
  38. 38.
    Posada J, Vichi P, Tritton TR (1989) Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 49:6634–6639Google Scholar
  39. 39.
    Rushmore TH, Pickett CB (1993) Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem 268:11475–11478Google Scholar
  40. 40.
    Sahyoun N, Wolf M, Besterman J, Hsieh TS, Sander M, LeVine H, Chang KJ, Cuatrecasas P (1986) Protein kinase C phosphorylates topoisomerase II: topoisomerase II activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 83:1603–1607Google Scholar
  41. 41.
    Sampson KE, Wolf CL, Abraham I (1993) Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Letters 58:7–14Google Scholar
  42. 42.
    Sato W, Yusa K, Naito M, Tsuruo T (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Comm 173:1252–1257Google Scholar
  43. 43.
    Satoh T, Nakafuku M, Kaziro Y (1992) Function of Ras as a molecular switch in signal transduction. J Biol Chem 267:24149–24152Google Scholar
  44. 44.
    Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human cancer. Pharmacol Ther 52:385–406Google Scholar
  45. 45.
    Sklar MD (1988) Increased resistance tocis-diamminedichloroplatinum (II) in NIH 3T3 cells transformed by ras oncogene. Cancer Res 48:793–797Google Scholar
  46. 46.
    Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M (1992) DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3:323–330Google Scholar
  47. 47.
    überall F, Maly K, Egle A, Doppler W, Hofmann J, Grunicke HH (1991) Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res 51:5821–5825Google Scholar
  48. 48.
    Uchiumi T, Kohno K, Tanimura H, Hidaka K, Asakuno K, Abe H, Uchida Y, Kuwano M (1993) Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett 325:11–16Google Scholar
  49. 49.
    Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA (1992) Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413–429Google Scholar
  50. 50.
    Vojtek AB, Hollenberg SM, Cooper JA (1993) Mammalian ras interacts directly with the serine/threonine kinase raf. Cell 74:205–214Google Scholar
  51. 51.
    Warne PH, Viciana PR, Downward J (1993) Direct interaction of ras and the amino-terminal region of raf-1 in vitro. Nature 364:352–355Google Scholar
  52. 52.
    Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Susuku K, Tsuruo K, Cowan KH, Glaszer RI (1991) Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181–188Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • H. Grunicke
    • 1
  • J. Hofmann
    • 1
  • I. Utz
    • 1
  • F. überall
    • 1
  1. 1.Institut für Medizinische Chemie und BiochemieUniversität InnsbruckInnsbruckAustria

Personalised recommendations